Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Publisher Correction: Long-Term Health-Related Quality of Life in Patients with Plaque Psoriasis Treated with Certolizumab Pegol: Three-Year Results from Two Randomised Phase 3 Studies (CIMPASI-1 and CIMPASI-2).

Autor: Gisondi P; Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy., Gottlieb AB; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Elewski B; Department of Dermatology, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA., Augustin M; Institute for Health Services Research in Dermatology and Nursing (IVDP), University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany., McBride S; Royal Free London NHS Foundation Trust, London, UK., Tsai TF; Department of Dermatology, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan., de la Loge C; PCOM Analytics, Avallon, France., Fierens F; UCB Pharma, Brussels, Belgium., López Pinto JM; UCB Pharma, Madrid, Spain., Tilt N; UCB Pharma, Slough, UK., Lebwohl M; Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. lebwohl@aol.com.

Publikováno v: Dermatology and therapy [Dermatol Ther (Heidelb)] 2023 Jun; Vol. 13 (6), pp. 1389-1390.